Submitted by Anonymous (not verified) on 19 September 2024 - 10:40
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Uro-nephrology, PIP number: P/0388/2023
Source: